Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lots of Questions
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1202)
•••
Comment by Duster340on Mar 09, 2024 5:32pm
387 Views
Post# 35924737

RE:RE:RE:RE:RE:RE:Lots of Questions

RE:RE:RE:RE:RE:RE:Lots of Questions
Montana5 wrote: Maybe with the way ATE respectfully waived the white flag on the arbitration, could it be possible that Nuance might be agreeable to a graduated payback that might benefit the completion of P2 and the potential of securing a new partnership agreement? We know the amount of the settlement, but under what terms and conditions? I'm hoping ATE will be providing more information this week with their plan of action.
anything is possible but is nuance willing to take that risk unlikely, if they did agree to a deal that kicks payment down the road antibe will burn through the cash with P2 but what if otena is unsuccessful ATE will be bankrupt and nuance will also lose out on there 24M that they have in the bag right now.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities